Home > News > Asklepios Bio and Bayer Healthcare Sign Research Deal
June 3rd, 2005
Asklepios Bio and Bayer Healthcare Sign Research Deal
Abstract:
Asklepios is currently conducting preclinical testing of a synthetically designed biological nano particle (BNP) gene therapy, containing the factor IX gene for the treatment of hemophilia B.
Source:
triangletechjournal.com
Bookmark:
| Related Links |
Asklepios Biopharmaceutical Inc.
| Related News Press |
Investments/IPO's/Splits
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018
Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018
180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018
Nanomedicine
Getting a better look at living cells April 25th, 2018
Biophysics -- lighting up DNA-based nanostructures April 25th, 2018
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
Announcements
Getting a better look at living cells April 25th, 2018
Graphene origami as a mechanically tunable plasmonic structure for infrared detection April 25th, 2018
Nuclear radiation detecting device could lead to new homeland security tool: New device can detect gamma rays and identify radioactive isotopes April 25th, 2018
Biophysics -- lighting up DNA-based nanostructures April 25th, 2018
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||